Skip to content


High quality lab testing made more convenient and comfortable for consumers and patients by enabling self-collection via TAP II wherever needed

BOSTON, Mass., FEBRUARY 2, 2021 – Seventh Sense Biosystems, Inc. (7SBio), developers of the world’s first push-button blood collection device, announced today that the company has received CE mark approval from the European Commission for its TAP® II blood collection device. This clearance opens up European Union markets for consumers and patients to access simple, convenient, and more comfortable blood collection at home, all at the push of a button.

“We’re very excited to bring TAP II into the European marketplace with the CE marking approval. This clearance, and the support from our investors, paves the way for our innovative blood collection technology to enter the homes of our European customers and to provide easier access to healthcare services,” said Rick Bente, CEO of 7SBio. “Seventh Sense’s vision to revolutionize the way the world draws blood is now ready for the world’s stage, and with the COVID-19 pandemic transforming how healthcare is delivered to consumers, it could not come at a better time.”

Seventh Sense has raised over $80 million to date in pursuit of this mission and continues to advance its proprietary micro-needle technology used in its CE-marked and FDA-approved TAP® device. The second-generation TAP II device expands the volume of blood that can be collected while delivering standardized and detachable serum and plasma collection containers that fit seamlessly into laboratory workflows.

The process is simple. A patient places TAP II on their upper arm and presses a button on the device to begin blood collection. The process to collect blood takes only two to three minutes. After collection is complete, the device is sent back to a lab for analysis.

“We believe that the simple blood collection process enabled by TAP II not only will help shape telehealth in general, but it also helps to keep the public safer during the COVID-19 pandemic,” said Chris Moriarty, CEO at Affinity Biomarker Labs. “As a lab providing both direct-to-patient testing and lab services for consumer healthcare companies, our patients and customers appreciate the ease and more comfortable experience of using TAP II, and the convenience of safe and effective blood collection without leaving home.”

The current standard of care for blood collection is phlebotomy, which requires medical professionals, large needles, and in-person appointments to collect blood. However, TAP II can be used in place of traditional venipuncture or fingerstick blood collection for many applications in both professional and at-home settings.

With CE mark clearance for TAP II, 7SBio’s mission to make blood collection simple, convenient, and more comfortable has arrived for European customers.

About YourBio Health

YourBio Health is a Flagship Pioneering portfolio company that invented ‘Touch-Activated Phlebotomy’ (TAP) for virtually painless whole capillary blood collection using devices incorporating patented technology. This technology eliminates barriers to blood collection by allowing a capillary blood sample to be collected from any physical location without the pain of a fingerstick or the need for traditional phlebotomy. Backed by the latest sciences, data management technology, and certified central laboratories, YourBio Health is seeking to revolutionize and humanize the blood collection process serving clinical trials, and diagnostic and wellness applications.

Media Contact:
Connor Halverson
That’s Nice LLC, on behalf of YourBio Health
Tel: +1 212 366 4455

SOURCE YourBio Health